

# Novocastra Predilute CMV Probe

## Product Code: ISH5719-A

### Analyte Specific Reagent

**Intended Use** This reagent is an analyte specific reagent. Analytical and performance characteristics are not established.

**Reagent Provided** CMV Probe is a fluorescein-conjugated oligonucleotide probe supplied in hybridization solution.  
Total volume = 7 mL.

**Specificity** Human cytomegalovirus early gene transcript.

### Warnings and Precautions

**CMV PROBE**

Contains Formamide (<50%) and Dextran Sulphate (<30%).  
GHS07: Exclamation mark.  
GHS08: Health hazard.  
Signal words: Danger.

H315: Causes skin irritation.  
H319: Causes serious eye irritation.  
H360D: May damage the unborn child.

P201: Obtain special instructions before use.  
P202: Do not handle until all safety precautions have been read and understood.  
P260: Do not breathe dust/fumes/gas/mist/vapours/spray.  
P281: Use personal protective equipment as required.  
P308 + P313: IF exposed or concerned: Get medical advice/attention.  
P314: Get medical advice/attention if you feel unwell.  
P264: Wash thoroughly after handling.  
P280: Wear protective gloves/protective clothing/eye protection/face protection.  
P305 + P351 + P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
P337 + P313: If eye irritation persists: Get medical advice/attention.  
P302 + P352: IF ON SKIN: Wash with plenty of soap and water.  
P332 + P313: If skin irritation occurs: Get medical advice/attention.  
P362: Take off contaminated clothing and wash before reuse.  
Restricted to professional users.

For additional information on toxicity please refer to the Material Safety Data Sheet (MSDS), which is available upon request, alternatively visit [www.LeicaBiosystems.com](http://www.LeicaBiosystems.com)

### Statement of Quality

Each lot of reagent has been quality controlled by in situ hybridization staining.

### Storage and Stability

Store at 2–8 °C in the dark. The product is stable under these conditions up to the expiry date indicated on the vial label.





**B I O S Y S T E M S**

**General References**

Bissinger AL., Singzer C, Kaiserling E et al. Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. *Journal of Medical Virology* 2002;67:200–206.

Pass RF, Fowler KB, Boppana SB et al. Congenital CMV infection following first trimester maternal infection: Symptoms at birth and outcomes. *Journal of Medical Virology* 2006;35:216–220.

Singh N. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies. *Journal of Medical Virology*. 2006;35(4):474–477.

Erice A, Tierney C, Hirsch M et al. AIDS Clinical Trials Group Protocol 360 Study Team. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS Clinical Trials Group Protocol 360). *Clinical Infectious Diseases* 2003;37(4):567–78.

Wu TC, Lee WA, Pizzorno MC et al. Localization of the human cytomegalovirus 2.7-kb major early beta-gene transcripts by RNA in situ hybridization in permissive and non permissive infections. *American Journal of Pathology*. 1992 141: 1247–1254.

Clinical Laboratory Improvement Amendments of 1988, Final Rule 57 FR 7163 February 28, 1992.

Villanova PA. National Committee for Clinical Laboratory Standards (NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. 1991; 7(9). Order code M29-P.

Wilkinson DG. The theory and practice of in situ hybridization. In: Wilkinson DG. (ed.) *In Situ Hybridization A practical approach*. 2nd Edition. New York: Oxford University Press, 1998, pp. 18–20.

**Date of Issue**

02 March 2015